Recent advances in the treatment of acute leukemia: 1999

Current Opinion in Hematology

Volumn 7, Issue 4, 2000, Pages 205-211

  Berman, Ellin ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HD 37; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE INHIBITOR; RETINOIC ACID; TIOGUANINE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CYTOGENETICS; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD; CHROMOSOME ABERRATIONS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DNA, NEOPLASM; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; INFANT; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; MULTICENTER STUDIES; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; TRETINOIN;

EID: 0034096992     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200007000-00002     Document Type: Review

References (31)

1. 1 Speck NA, Stacy T, Wang Q, North T, Gu T-L, Miller J, et al.: Core-binding factor: a central player in hematopoiesis and Leukemia. Cancer Res 1999, 59(suppl):1789s-1793s. This is an excellent review of the CBFs and their role in hematopoiesis.
2. 2 Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al., on behalf of the Medical Research Council Adult and Children's Leukemia Working Party: The importance of diagnostic cytogenetics on outcome in AML analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998, 92:2322-2333. This is the largest cytogenetic study to date that correlated karyotype with clinical response.
3. 3 Bloomfield C, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al.: Frequency of prolonged remission duration after high dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subgroup. Cancer Res 1998, 58:4173-4179. This is the first study to show that the effect of high-dose cytarabine is correlated with karyotype.
4. 50 of blasts from patients with other abnormalities.
5. 5 Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, et al.: Expression of chromosome 21-localized gene in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blasts cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999, 94:1393-1400. This study shows the increased chemosensitivity of blasts from children with Down syndrome.
6. 6 Schreiner SA, Garcia-Cuellar MP, Fey GH, Slany RK: The leukemogenic fusion of MLL and ENL creates a novel transcriptional transactivator. Leukemia 1999, 13:1525-1533. This study shows that the fusion protein MLL-ENL activates several unrelated promotors including the promoter for Hoxa7.
7. 7 Mrozek K, Heininen K, Lawrence D, Carroll AJ, Kodura PRK, Rao KW, et al.: Adult patients with de novo acute myeloid leukemia and t(9;11) (p22;q23) have a superior outcome to patients with other translocations involving band q23: a Cancer and Leukemia Group B study. Blood 1997, 90:4532-4538.
8. 8 Lo Coco F, Nervi C, Awisati G, Mandelli F: Acute promyelocytic leukemia: a curable disease. Leukemia 1998, 12:1866-1880. This is an excellent review of this disease with an extensive section on therapy.
9. 9 Jansen JH, de Ridder MC, Geertsma WMC, Erpelinck CAJ, van Lom K, Smit EME, et al.: Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all trans retinoic acid and granulocyte colony stimulating factor. Blood 1999, 94:39-45. This is a case report of a patient with this translocation who did not respond to ATRA but did respond to the combination of ATRA plus granulocyte colony-stimulating factor.
10. 10 Warrell RP, He L-Z, Richon V, Calleja E, Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998, 90:1621-1625. Clinical treatment with an inhibitor of histone deacetylase may restore sensitivity to the antileukemic effect of ATRA.
11. 11 Shen Z-X, Chen Z-Q, Ni J-H: Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): II: clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
12. 12 Soignet SL, Maslak P, Wang Z-G, Jhanwar S, Calleja E, Dardashti LJ, et al.: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:134-138. This is one of the first papers to describe the effect of arsenic in patients with relapsed APL.
13. 13 Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, et al.: Arsenic trioxide as an inducer of apoptosis and loss of PML/RARalpha protein in acute promyelocytic cells. J Natl Cancer Inst 1998, 90:124-133. This study shows that arsenic induces apoptosis without differentiation in retinoic acid-sensitive and -resistant cell lines at concentrations that are achievable in patients.
14. 14 Wang Z-G, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, et al.: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML RAR-alpha independent manner. Blood 1998, 92:1497-1504. Inorganic trioxide and the organic arsenical melarsoprol inhibit growth and induce apoptosis in a variety of myeloid leukemia cell lines.
15. 15 Jing Y, Dai J, Chalmers RME, Tatton WG, Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide dependent pathway. Blood 1999, 94:2102-2111. The induction of apoptosis by arsenic involves an early decrease in cellular mitochondrial membrane potential and increases hydrogen peroxide content.
16. 16 Li YM, Broome J: Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 1999, 59:776-780. Arsenic inhibits guanosine thriphosphate-induced polymerization and microtubule formation in vitro.
17. 17 Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al., for the European APL Group: A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance chemotherapy in newly diagnosed acute promyelocytic leukemia. Blood 1999, 94:1192-1200. This very well designed study shows that the early addition of chemotherapy to ATRA and maintenance therapy combining continuous chemotherapy and intermittent ATRA can reduce the incidence of relapse in APL.
18. 18 Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, et al., for the Pethema Group: A modified AIDA protocol with anthracycline based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα positive acute promyelocytic leukemia. Blood 1999, 94:3015-3021. This study shows that a less intense consolidation with idarubicin or mitoxantrone alone followed by maintenance chemotherapy plus ATRA results in a very high disease-free survival rate.
19. 19 Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, Scotto KW: Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to daunorubicin. Clin Cancer Res 1999: 5:3352-3356. This provocative study showed a marked increase in MDR1 expression in metastatic sarcoma specimens after a 50-minute exposure in vivo.
20. 20 Lee EJ, George SL, Caliguir M, Szatrowski T, Powell B, Lemke S, et al.: Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC0833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B Study 9420. J Clin Oncol 1999, 17:2831-2839. This study in 120 patients 60 years of age or older showed it is necessary to decrease the dose of daunorubicin and etoposide when administered with PSC-833.
21. 21 Advani R, Saba HI, Tallman M, Rowe JM, Wiernik PH, Ramek J, et al.: Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999, 93:787-795. This small phase II trial showed a decrease in the clearance of etopside and mitoxantrone and a 32% remission incidence in this heavily treated group of patients.
22. 22 List AF, Kopecky KJ, Willman CL, Spier C, Dorr R, Flaherty L, et al.: Benefit of cyclosporin (CsA) modulation of anthracycline resistance in high risk AML: a Southwest Oncology Group (SWOG) study [abstract]. Blood 1998, 92(suppl 1):213. This abstract showed a significant difference in 3-year relapse-free survival in patients who received cyclosporine compared with patients who received chemotherapy alone.
23. 23 Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantracahi R, Block AW, et al.: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999, 93:3983-3993. This is a prospective analysis of the impact of karyotype in 256 adults with ALL.
24. 24 Raynaud SD, Dastugue N, Zoccola D, Shurtleff SA, Mathew S, Raimondi SC: Cytogenetic abnormalities associated with t(12;21): a collaborative study of 169 children with t(12;21)-positive acute lymphoblastic leukemia. Leukemia 1999, 13:1325-1330. This paper shows that the cryptic abnormality is associated with additional abnormalities such as structural changes, rearrangements, and nonspecific deletions.
25. 25 Wiemels JL, Ford AM, Van Wering ER, Postma A, Greaves M: Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML gene fusion in utero. Blood 1999, 94:1057-1062. This is a provocative case report of twins who developed ALL 9 years apart. Both had the TEL-AML gene product.
26. 26 Rubnitz JE, Camitta BM, Mahmoud H, Raimondi SC, Carroll AJ, Borowitz MJ, et al.: Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. J Clin Oncol 1999, 17:191-196. This study shows that this abnormality can produce either a T-or a B-cell phenotype and that the clinical outcome varies according to age and phenotype.
27. 27 Ito C, Kumagi M, Manabe A, Coustan-Smith E, Raimondi SC, Behm FG, et al.: Hyperdiploid acute lymphoblastic leukemia with 51-65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. Blood 1999, 93:315-320. This study showed that blasts with a hyperdiploid karyotype had a marked propensity to undergo apoptosis in a marrow-derived stromal cell culture.
28. 28 Knechtli CJC, Goulden NJ, Hancock JP, Grandage VLG, Harris EL, Garland RJ, et al.: Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998, 92:4072-4079. This study showed that minimal residual disease detected prior to allogeneic bone marrow transplantation correlated closely with 2-year disease-free survival.
29. 29 Lo Nigro L, Cazzaniga G, Di Cataldo A, Pannunzio A, D'Aniello E, Masera G, et al.: Clonal stability in children with acute lymphoblastic leukemia (ALL) who relapsed five or more years after diagnosis. Leukemia 1999, 13:190-195. At least one stable rearranged allele of the T-cell receptor was traced in all five patients with relapsed ALL.
30. 30 Uckun FM, Messinger Y, Chen C-L, Myers DE, Goldman F, Hurvitz C, et al.: Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19 directed tyrosine kinase inhibitor. Clin Cancer Res 1999, 5:3906-3913. This provocative study showed clinical activity of the CD19 receptor-directed tyrosine kinase inhibitor B43-genistein in a small group of heavily treated patients.
31. 31 Ghetie M-A, Ghetie V, Vitetta ES: Anti CD-19 antibodies inhibit the function of the P-gp pump in multidrug resistant B lymphoma cells. Clin Cancer Res 1999, 5:3920-3927. The anti-CD19 monoclonal antibody HD37 inhibited the efflux of rhodamine-123 from an MDR lymphoma cell line; no evidence was found for recognition of a cross-reactive epitope on P glycoprotein or modulation of P glycoprotein on the cell surface.